NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
This article was originally published in The Pink Sheet Daily
Executive Summary
A lack of good clinical trial data on the use of Sprycel, high-dose Glivec and Tasigna in imatinib-resistant chronic myeloid leukemia patients leads to rejection by NICE in a draft guidance.
You may also be interested in...
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.
Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence